China Pharmaceutical University has patented new isochromanone compounds acting as proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors. As such, they are described as potentially useful for the treatment of atherosclerosis, obesity, hepatic steatosis, hypercholesterolemia, hyperlipidemia and hypertriglyceridemia.